930 DALI lifestyle intervention in pregnant women with BMI ≥29 kg

930
DALI lifestyle intervention in pregnant women with BMI ≥29 kg/m2. Continuous glucose
monitoring substudy
D. Tundidor1, A. Zawiejska2, E. Mathiesen3, U. Mantag2, E. Wender-Ozegowska2, P. Damm3, A. de
Leiva1, R. Corcoy1, DALI Core Study Group;
1
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2University of Medical Sciences, Poznan,
Poland, 3Righospitalet, Copenhagen, Denmark.
Background and aims: The DALI study compared the impact of three interventions (healthy eating
(HE), physical activity (PA), and HE + PA) vs a control group on the risk of GDM in a randomised
controlled trial conducted in 9 European countries. In a subset of three of the participating centers, we
performed a substudy investigating possible differences between the groups in 24h glucose values
using continuous glucose monitoring (CGM). We aimed to compare average and variability of 24h
glucose values measured by CGM in the four study groups.
Materials and methods: Pregnant women at risk of GDM (pre-pregnancy BMI ≥29 Kg/m2), ≤19+6
weeks of gestation, with normal glucose tolerance at baseline (IADPSG criteria) were included. The
intervention was conducted by personal coaches, who had received standardized motivational
interviewing training, and consisted of five face-to-face interviews and up to four telephone sessions.
At 35-37 weeks CGM (iPro2, Medtronic) was performed for three days (minimum CGM information
> 60% of the period required for inclusion). Sixty-four out of 198 women were included in the CGM
substudy. Statistical analysis: variables are expressed as %, mean ± standard deviation or P50 (P25,
P75) according to distribution; Chi-square test, ANOVA and Kruskal-Wallis ANOVA used for
comparison.
Results: See table 1
Conclusion: In pregnant women with pre-pregnancy BMI ≥29 Kg/m2, lifestyle interventions did
neither modify the average or variability of 24h glucose values measured by CGM at 35-37 weeks of
gestation.
Clinical Trial Registration Number: ISRCTN70595832
Supported by: HEALTH-F2—2009-242187
Disclosure: D. Tundidor: None.